Cargando…
Patient-Centric Approaches for Phase I Combination Trials Come on Stage
A disruptive clinical trial design allowed Drilon and colleagues to demonstrate proof of concept of the potential of PF-07284892 to overcome resistance mechanisms to targeted therapies in the clinic. See related article by Drilon et al., p. 1789 (7).
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Association for Cancer Research
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401070/ https://www.ncbi.nlm.nih.gov/pubmed/37269291 http://dx.doi.org/10.1158/2159-8290.CD-23-0534 |